![]() |
市場調查報告書
商品編碼
1681016
2025-2035 年全球骨密度儀市場Global Bone Densitometer Market 2025-2035 |
骨密度儀市場規模、佔有率和趨勢分析報告,按技術(軸向骨密度測量和外周骨密度測量)、應用(骨質疏鬆症和骨質減少症診斷、囊性纖維化診斷、慢性腎病診斷、類風濕性關節炎診斷和身體組成測量)和最終用戶(醫院、骨科診所和診斷成像中心)預測期(2025-2035 年)
行業概覽
Bone Densitometer Market Size, Share & Trends Analysis Report by Technology (Axial Bone Densitometry, and Peripheral Bone Densitometry), Application (Osteoporosis and Osteopenia Diagnosis, Cystic Fibrosis Diagnosis, and Chronic Kidney Diseases Diagnosis, Rheumatoid Arthritis Diagnosis, and Body Composition Measurement), and End-User (Hospitals, Orthopedic Clinics, and Diagnostic Imaging Centers) Forecast Period (2025-2035)
Industry Overview
Bone densitometer market is anticipated to grow at a CAGR of 4.4% during the forecast period (2025-2035). The increasing prevalence of osteoporosis and osteopenia globally, coupled with a growing geriatric population, is a key demand driver for bone densitometry. Increased healthcare spending combined with technological advancement, awareness programs, and promotion have made it more accessible. In emerging markets, increased healthcare expenditure has driven better diagnostics infrastructure and adoption of advanced equipment. Preventive care is additionally driving routine BMD testing. Sports-related injuries and lifestyle diseases are on the increase, with broader clinical utilization of bone densitometry for conditions such as rheumatoid arthritis, chronic kidney disease, and obesity-related bone disorders.
Market Dynamics
Rising Prevalence of Osteoporosis
The International Osteoporosis Foundation reports a global rise in osteoporosis cases, especially among the aging population, with women at a higher risk post-menopause. According to the International Osteoporosis Foundation, in February 2024, osteoporosis has a considerable influence on older adults, with one in two women and up to one in four men over age 50 likely to experience a bone fracture due to the condition. It is estimated that 75 million people in Europe, the US, and Japan are affected by osteoporosis. Most hip fractures occur in elderly patients whose bones have become weakened by osteoporosis. The US experiences approximately 300,000 hip fractures annually, with a 25% mortality rate within a year post-fracture. Additionally, 25% of patients transition from the hospital to a nursing home permanently, while the remaining 50% are unable to regain their previous level of function. Six months after a hip fracture, only 15% of individuals can walk across a room unaided. Projections estimate that between 2018 and 2040, annual fractures will increase by 68% from 1.9 million to 3.2 million, with related costs increasing annually from $57 billion to more than $95 billion.
Rising Aging Population Driving Market Growth
The increasing aging population is increasing the demand for bone health diagnostics, as older adults are at a higher risk of osteoporosis and fractures due to declining bone density. According to the World Health Organization, in October 2024, all countries encountered significant challenges in preparing their health and social systems for the demographic transition ahead. By 2050, 80% of older adults will reside in low- and middle-income countries, and the aging process is accelerating more rapidly than before. In 2020, the population aged 60 years or over surpassed the number of children under 5 years old, and between 2015 and 2050, the proportion of the global population aged 60 years or over will increase from 12% to 22%. One in six people in the world will be 60 years or older by 2030, and the population aged 60 years or over will rise from 1 billion in 2020 to 1.4 billion.
Market Segmentation
Axial Bone Densitometry Segment to Lead the Market with the Largest Share
Axial bone densitometry is a procedure used to measure the density of the central skeleton, which includes the spine, pelvis, and hip. It is utilized for the diagnosis of osteoporosis, monitoring the treatment of osteoporosis, evaluation of fracture risk, assessment of bone loss, and detection of metabolic bone disorders. It is most helpful for postmenopausal women, elderly patients, and patients with risk factors such as history of fractures or family history. The technique is recommended for high-risk populations such as postmenopausal women, elderly people, low-trauma fracture survivors, and individuals with specific risk factors.
Osteoporosis and Osteopenia Diagnosis: A Key Segment in Market Growth
Bone densitometry tests, or DEXA scans, diagnose osteoporosis and osteopenia by determining bone mineral density (BMD). These tests detect bone degeneration diseases, such as osteoarthritis, osteomalacia, and osteoporotic fractures. The results are compared with the average BMD of a healthy individual. Testing can predict future fractures, monitor the effects of treatment, and confirm the diagnosis of osteoporosis in post-fracture patients. In elderly patients, early treatment prevents severe complications.
The global bone densitometer market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America)
Government and Private Healthcare Initiatives in Asia-Pacific
In Asia-Pacific, osteoporosis is greatly underdiagnosed and undertreated. Public health programs on bone health and the prevention of osteoporosis are essential in reducing healthcare costs and improving quality of life, especially when government agencies collaborate with private healthcare providers. For instance, in October 2024, the India Bone Health Initiative, IBHI, was recently launched by Pharmed Ltd. and coincided with World Osteoporosis Day. The initiative targets the improvement of the health and well-being of the Indian population by creating an awareness of osteoporosis, educating patients, making BMD testing accessible, early detection and prevention strategies, and collaborating with healthcare professionals. The initiative capitalizes on Pharmed's history of success with bone health initiatives, including conducting free BMD screening camps and collaborating with orthopaedicians. It seeks to develop a setting in which patients are better informed about bone health, yet less able to have meaningful discussions with healthcare providers.
North America Region Dominates the Market with Major Share
North America holds a significant share owing to the aging North American population increasing the demand for bone densitometers, which are vital diagnostic tools for monitoring bone health. According to the Population Reference Bureau's (PRB) Org., in January 2024, the American population aged 65 and older is expected to grow significantly, from 58 million in 2022 to 82 million by 2050, representing a 47% increase. This age group's proportion of the total population is anticipated to rise from 17% to 23%. Additionally, the median age of the US population has increased from 30.0 in 1980 to 38.9 in 2022, with 17 states having a median age above 40, led by Maine at 44.8 and New Hampshire at 43.3. The older population is also growing more racially and ethnically diverse, with the percentage of people who identify as non-Hispanic white expected to decline from 75 percent in 2022 to 60 percent by 2050.
The major companies operating in the global bone densitometer market include General Electric Co., Hitachi, Ltd., Hologic, Inc., FUJIFILM Holdings Corp., Echolight S.p.a., JNC International Ltd., and Xingaoyi Medical Equipment Co., Ltd. among others. Market players are leveraging partnerships, collaborations, mergers and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments